Guggenheim lowered the firm’s price target on Adaptimmune to $4 from $5 and keeps a Buy rating on the shares after the company announced 2Q results and is now guiding to an afami-cel BLA submission completion in Q4, versus mid-2023 previously. The firm’s lower target reflects a launch delay.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ADAP: